Cargando…

Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland

The assessment of IGF-1 concentrations is one of the parameters used for evaluating response to rhGH treatment. An increase in IGF-1 concentration positively correlates with growth improvement, whereas IGF-1 concentrations significantly above the reference range may increase the risk of possible sid...

Descripción completa

Detalles Bibliográficos
Autores principales: Glińska, Marta, Walczak, Mieczysław, Wikiera, Beata, Pyrżak, Beata, Majcher, Anna, Paluchowska, Monika, Gawlik, Aneta, Antosz, Aleksandra, Kusz, Marcin, Bossowski, Artur, Stożek, Karolina, Wędrychowicz, Anna, Starzyk, Jerzy, Petriczko, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342595/
https://www.ncbi.nlm.nih.gov/pubmed/37445427
http://dx.doi.org/10.3390/jcm12134392
_version_ 1785072536564793344
author Glińska, Marta
Walczak, Mieczysław
Wikiera, Beata
Pyrżak, Beata
Majcher, Anna
Paluchowska, Monika
Gawlik, Aneta
Antosz, Aleksandra
Kusz, Marcin
Bossowski, Artur
Stożek, Karolina
Wędrychowicz, Anna
Starzyk, Jerzy
Petriczko, Elżbieta
author_facet Glińska, Marta
Walczak, Mieczysław
Wikiera, Beata
Pyrżak, Beata
Majcher, Anna
Paluchowska, Monika
Gawlik, Aneta
Antosz, Aleksandra
Kusz, Marcin
Bossowski, Artur
Stożek, Karolina
Wędrychowicz, Anna
Starzyk, Jerzy
Petriczko, Elżbieta
author_sort Glińska, Marta
collection PubMed
description The assessment of IGF-1 concentrations is one of the parameters used for evaluating response to rhGH treatment. An increase in IGF-1 concentration positively correlates with growth improvement, whereas IGF-1 concentrations significantly above the reference range may increase the risk of possible side effects. The aim of this study was to evaluate the IGF-1 local reference ranges for the rhGH treatment centers concerned and to compare these values with the population reference ranges. A retrospective analysis was conducted on auxological data from 229 SGA patients who received rhGH treatment between 2016 and 2020 at six university clinical centers in Poland. The IGF-1 levels were assessed at baseline, after 12 and 24 months, and compared to the reference ranges provided by the local laboratory and to the population reference ranges. After 12 months, 56 patients (24%) presented IGF-1 values > 97th percentile for the local reference range, whereas only 8 (3.5%) did so using the population reference ranges; p < 0.001. After 24 months of treatment, the values were: 47 (33%) > 97th percentile by local vs. 6 (4.2%) by population standards; p < 0.001. Thirty-nine patients had rhGH dose reduced after 12 months, of whom twelve (25%) had IGF-1 > 97th percentile according to the local reference ranges and five (13%) > 97th percentile for the population. Our data suggest that different methods used to determine IGF-1 concentration and the different IGF-1 reference ranges result in a significant proportion of rhGH-treated children with elevated IGF-1 concentration and experiencing dose reductions, which may negatively affect growth rate.
format Online
Article
Text
id pubmed-10342595
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103425952023-07-14 Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland Glińska, Marta Walczak, Mieczysław Wikiera, Beata Pyrżak, Beata Majcher, Anna Paluchowska, Monika Gawlik, Aneta Antosz, Aleksandra Kusz, Marcin Bossowski, Artur Stożek, Karolina Wędrychowicz, Anna Starzyk, Jerzy Petriczko, Elżbieta J Clin Med Article The assessment of IGF-1 concentrations is one of the parameters used for evaluating response to rhGH treatment. An increase in IGF-1 concentration positively correlates with growth improvement, whereas IGF-1 concentrations significantly above the reference range may increase the risk of possible side effects. The aim of this study was to evaluate the IGF-1 local reference ranges for the rhGH treatment centers concerned and to compare these values with the population reference ranges. A retrospective analysis was conducted on auxological data from 229 SGA patients who received rhGH treatment between 2016 and 2020 at six university clinical centers in Poland. The IGF-1 levels were assessed at baseline, after 12 and 24 months, and compared to the reference ranges provided by the local laboratory and to the population reference ranges. After 12 months, 56 patients (24%) presented IGF-1 values > 97th percentile for the local reference range, whereas only 8 (3.5%) did so using the population reference ranges; p < 0.001. After 24 months of treatment, the values were: 47 (33%) > 97th percentile by local vs. 6 (4.2%) by population standards; p < 0.001. Thirty-nine patients had rhGH dose reduced after 12 months, of whom twelve (25%) had IGF-1 > 97th percentile according to the local reference ranges and five (13%) > 97th percentile for the population. Our data suggest that different methods used to determine IGF-1 concentration and the different IGF-1 reference ranges result in a significant proportion of rhGH-treated children with elevated IGF-1 concentration and experiencing dose reductions, which may negatively affect growth rate. MDPI 2023-06-29 /pmc/articles/PMC10342595/ /pubmed/37445427 http://dx.doi.org/10.3390/jcm12134392 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Glińska, Marta
Walczak, Mieczysław
Wikiera, Beata
Pyrżak, Beata
Majcher, Anna
Paluchowska, Monika
Gawlik, Aneta
Antosz, Aleksandra
Kusz, Marcin
Bossowski, Artur
Stożek, Karolina
Wędrychowicz, Anna
Starzyk, Jerzy
Petriczko, Elżbieta
Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland
title Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland
title_full Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland
title_fullStr Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland
title_full_unstemmed Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland
title_short Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland
title_sort difficulties in interpreting igf-1 levels in short stature children born small for gestational age (sga) treated with recombinant human growth hormone (rhgh) based on data from six clinical centers in poland
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342595/
https://www.ncbi.nlm.nih.gov/pubmed/37445427
http://dx.doi.org/10.3390/jcm12134392
work_keys_str_mv AT glinskamarta difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT walczakmieczysław difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT wikierabeata difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT pyrzakbeata difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT majcheranna difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT paluchowskamonika difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT gawlikaneta difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT antoszaleksandra difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT kuszmarcin difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT bossowskiartur difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT stozekkarolina difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT wedrychowiczanna difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT starzykjerzy difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland
AT petriczkoelzbieta difficultiesininterpretingigf1levelsinshortstaturechildrenbornsmallforgestationalagesgatreatedwithrecombinanthumangrowthhormonerhghbasedondatafromsixclinicalcentersinpoland